BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 30653948)

  • 1. Circulating miR-26a, miR-106b, miR-107 and miR-133b stratify hepatocellular carcinoma patients according to their response to transarterial chemoembolization.
    Ali HEA; Emam AA; Zeeneldin AA; Srour R; Tabashy R; El-Desouky ED; Abd Elmageed ZY; Abdel-Wahab AA
    Clin Biochem; 2019 Mar; 65():45-52. PubMed ID: 30653948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma micoRNA-122 as a predictive marker for treatment response following transarterial chemoembolization in patients with hepatocellular carcinoma.
    Kim SS; Nam JS; Cho HJ; Won JH; Kim JW; Ji JH; Yang MJ; Park JH; Noh CK; Shin SJ; Lee KM; Cho SW; Cheong JY
    J Gastroenterol Hepatol; 2017 Jan; 32(1):199-207. PubMed ID: 27194671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of serum microRNA expression in hepatocellular carcinomas treated with transarterial chemoembolization and patient survival.
    Liu M; Liu J; Wang L; Wu H; Zhou C; Zhu H; Xu N; Xie Y
    PLoS One; 2014; 9(10):e109347. PubMed ID: 25275448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigating the pretreatment miRNA expression patterns of advanced hepatocellular carcinoma patients in association with response to TACE treatment.
    El-Halawany MS; Ismail HM; Zeeneldin AA; Elfiky A; Tantawy M; Kobaisi MH; Hamed I; Abdel Wahab AH
    Biomed Res Int; 2015; 2015():649750. PubMed ID: 25811030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The elevated expression of serum glutathione reductase in hepatocellular carcinoma and its role in assessing the therapeutic efficacy and prognosis of transarterial chemoembolization.
    Zheng Q; Xu X; Weng J; Li M; Li B; Cao Y
    Free Radic Biol Med; 2024 Aug; 221():225-234. PubMed ID: 38815771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating MiRNA-373 as a Predictor of Response to Super-selective Transarterial Chemoembolization Bridging Therapy in Hepatocellular Carcinoma Patients Awaiting Liver Transplantation.
    Tork ASE; Kamel AAF; Zaki MA; Abo El-Wafa RAH; El-Assar OS; Ibrahim Abdelkarem OA
    Asian Pac J Cancer Prev; 2023 Jan; 24(1):291-299. PubMed ID: 36708579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma MicroRNA-21, 26a, and 29a-3p as Predictive Markers for Treatment Response Following Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma.
    Kim SS; Cho HJ; Nam JS; Kim HJ; Kang DR; Won JH; Kim J; Kim JK; Lee JH; Kim BH; Lee MY; Cho SW; Cheong JY
    J Korean Med Sci; 2018 Jan; 33(1):e6. PubMed ID: 29215815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum TSGF and miR-214 levels in patients with hepatocellular carcinoma and their predictive value for the curative effect of transcatheter arterial chemoembolization.
    Tang L; Zhang XM
    Ann Palliat Med; 2020 Jul; 9(4):2111-2117. PubMed ID: 32762227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postintervention Interleukin-6 (IL-6) Level, Rather than the Pretreatment or Dynamic Changes of IL-6, as an Early Practical Marker of Tumor Response in Hepatocellular Carcinoma Treated with Transarterial Chemoembolization.
    Wu Y; Fan W; Xue M; Zhong B; Zhang S; Wang Y; Yao W; Zhao Y; Li J
    Oncologist; 2019 Dec; 24(12):e1489-e1495. PubMed ID: 31249138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum miR-21, miR-26a and miR-101 as potential biomarkers of hepatocellular carcinoma.
    Zhuang C; Jiang W; Huang D; Xu L; Yang Q; Zheng L; Wang X; Hu L
    Clin Res Hepatol Gastroenterol; 2016 Sep; 40(4):386-96. PubMed ID: 26669589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of serum HIF-1α change following transarterial chemoembolization in hepatocellular carcinoma.
    Lin ZH; Jiang JR; Ma XK; Chen J; Li HP; Li X; Wu XY; Huang MS; Lin Q
    Clin Exp Med; 2021 Feb; 21(1):109-120. PubMed ID: 33037574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamic Changes in Circulating MicroRNA Levels in Liver Cancer Patients Undergoing Thermal Ablation and Transarterial Chemoembolization.
    Zavadil J; Juráček J; Čechová B; Andrašina T; Slabý O; Goldberg N
    Klin Onkol; 2019; 32(Supplementum1):164-166. PubMed ID: 31064190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PKM2 inhibition may reverse therapeutic resistance to transarterial chemoembolization in hepatocellular carcinoma.
    Martin SP; Fako V; Dang H; Dominguez DA; Khatib S; Ma L; Wang H; Zheng W; Wang XW
    J Exp Clin Cancer Res; 2020 Jun; 39(1):99. PubMed ID: 32487192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Possible Use of miR-223-3p as a Prognostic Marker in Transarterial Chemoembolization Treatment of Hepatocellular Carcinoma Patients.
    E Abdelaziz H; El-Guendy N; Radwan EM; Sharawi SK; El-Houseini ME; Abdel-Wahab AA
    Asian Pac J Cancer Prev; 2022 Dec; 23(12):4125-4135. PubMed ID: 36579994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum LAG-3 Predicts Outcome and Treatment Response in Hepatocellular Carcinoma Patients With Transarterial Chemoembolization.
    Guo M; Qi F; Rao Q; Sun J; Du X; Qi Z; Yang B; Xia J
    Front Immunol; 2021; 12():754961. PubMed ID: 34691076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MiR-125b Loss Activated HIF1α/pAKT Loop, Leading to Transarterial Chemoembolization Resistance in Hepatocellular Carcinoma.
    Wei X; Zhao L; Ren R; Ji F; Xue S; Zhang J; Liu Z; Ma Z; Wang XW; Wong L; Liu N; Shi J; Guo X; Roessler S; Zheng X; Ji J
    Hepatology; 2021 Apr; 73(4):1381-1398. PubMed ID: 32609900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum microRNA-210 as a predictive biomarker for treatment response and prognosis in patients with hepatocellular carcinoma undergoing transarterial chemoembolization.
    Zhan M; Li Y; Hu B; He X; Huang J; Zhao Y; Fu S; Lu L
    J Vasc Interv Radiol; 2014 Aug; 25(8):1279-1287.e1. PubMed ID: 24935355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating microRNAs panel as a diagnostic tool for discrimination of HCV-associated hepatocellular carcinoma.
    Ali HEA; Abdel Hameed R; Effat H; Ahmed EK; Atef AA; Sharawi SK; Ali M; Abd Elmageed ZY; Abdel Wahab AH
    Clin Res Hepatol Gastroenterol; 2017 Sep; 41(4):e51-e62. PubMed ID: 28750770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 25-OH-vitamin D deficiency identifies poor tumor response in hepatocellular carcinoma treated with transarterial chemoembolization.
    Wu YQ; Fan WZ; Xue M; Guo J; Wei JL; Wang Y; Yao W; Zhao Y; Li JP
    Clin Transl Oncol; 2020 Jan; 22(1):70-80. PubMed ID: 31183764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved clinical outcome using transarterial chemoembolization combined with radiofrequency ablation for patients in Barcelona clinic liver cancer stage A or B hepatocellular carcinoma regardless of tumor size: results of a single-center retrospective case control study.
    Ren Y; Cao Y; Ma H; Kan X; Zhou C; Liu J; Shi Q; Feng G; Xiong B; Zheng C
    BMC Cancer; 2019 Oct; 19(1):983. PubMed ID: 31640620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.